



Nutraceuticals for Prevention of Ophthalmic Diseases

¹Garima Soni and ^{2*}Pankaj Gupta

^{1,2*}School of Medical and Allied Sciences, K. R. Mangalam University, Sohna Road, Gurgaon-122103, Haryana, India

Received: 12 Mar 2020 / Accepted: 10 Apr 2020 / Published online: 1 Jul 2020

*Corresponding Author Email: gupta.aiims@gmail.com

Abstract

This review focuses on the vitamins, minerals and antioxidants that have been described for reducing the risk of eye related diseases. Nowadays there is insufficient source to recommend routine nutritional supplementation in healthy adults for prevention age related eye disease. Consumption of antioxidant rich foods and nutraceutical formulas reduced the risk of macular degeneration. Many formulated dietary supplements that are sold in the market were clinically proved for their efficacy to treat eye disease. Nutraceutical can offer some therapeutic potential in glaucoma management but to lack of clinical trials examine their benefits for glaucoma limits their current therapeutic use. There are many complications to treat cataract by surgery such as it may raise the intraocular pressure, iris prolapse, cystoid macular edema and posterior capsular opacification (PCO). Therefore, as an alternative food and nutraceutical is the best natural way to cure the eye diseases because of their presumed safety and therapeutic effects.

Keywords

Age- related macular degeneration, Glaucoma, Cataract, Antioxidants, Dietary supplements.

INTRODUCTION:

In Elderly people visual impairment is considered as health problems that significantly disturbs quality of life of millions worldwide. In developed countries, the most common cause of blindness in worldwide is Age- related macular degeneration. By the year 2050, in US the prevalence of AMD is anticipated to increase to 22 million while the global prevalence is predictable to increase to 288 million by the year 2040. Glaucoma is the second main cause of blindness after cataract. It is concomitant with increased ocular pressure and when left untreated, patients may experience their sight completely loss. It is usually characterized by structural changes to the optic nerve head.

In worldwide around 45 million people are blind, beyond 17.6 are cataract cases. As per national blindness survey, prevalence of blindness was reported about 8 % in the age group more than 50.

OPHTHALMIC DISEASES:

A. AGE RELATED MACULAR DEGENERATION (ARMD):

ARMD is an eye disease which is related to retina, due to this disease, the part of the retina called the macula is damaged. Due to damage of macula, the fine points are not clear. When it becomes growing, it destroys the central vision which is necessary for reading books, recognizing faces, watching television, sewing driving and performing other daily everyday jobs. It leads to severe vision loss in adults over age 50.

Conventionally ARMD is classified into two types mainly Dry (non-exudative, non-neovascular) form which is more common and presents as Geographical atrophy in its advanced stage. Wet (exudative, neovascular) form which is relatively less common but is associated with rapid advance to vision loss (1).

According to a recent clinical classification ARMD is divided into -

- Early AMD (drusen size more than 63µm less than 125µm)
- Intermediate AMD (drusen size more than 125µm)
- Late AMD (Neovascular AMD and geographical atrophy)

Its prevalence probable to rise as a consequence of exponential population ageing. Prevalence of AMD differs from 1.2 to 29.3 % (2). Three population based studies – The Beaver Dam Eye (3), The Rotterdam (4), and Blue Mountain Eye study (5) report the prevalence rates to be 1.7% in US, 1.4% in Australia and 1.2% in Netherland respectively. Jayshree MP report that higher prevalence was noted in females. Dry AMD was noted more than wet AMD and Late AMD was seen less than Early AMD. Jayshree diagnosed 120 patients with ARMD and revealed that when the age of subjects increased prevalence also increased and most of them were in the age group of 60-70. Early AMD (71.7%, n = 86) and Late AMD was seen 28.3% (n= 34).

Ritu Sharma *et al.* conclude that prevalence of dry AMD (20.5%) is evident in the population of Punjab which is facilitated individually by age (≥ 66 yrs), DBP (>80 mmHg), alcohol drinking and smoking.

Nupura *et al* reviewed and reported various antioxidants, vitamins, minerals, age related eye disease study like formulas and berry extracts.

1. ANTIOXIDANTS:

A. XANTHOPHYLLS:

Xanthophyll (phyloxanthins) are the compounds belonging to the carotenoid group. They are mainly found in dark green leafy vegetables and in egg yolk. They are yellow pigments because these carotenoids exist in high concentration in the macula that occur widely in nature and form one of two major division of the carotenoid group, the other division is formed by the carotene (1). Xanthophyll mainly composed of Macular pigments –Lutein and zeaxanthin as well as β carotene are known to have protective effects against eye diseases include AMD, cataract and retinitis pigmentosa (2).

These carotenoid act in the biological system as ability to filter short wavelength light which may help to protect the outer retina and retinal pigment epithelium from oxidative stress, a modulator in the signal transduction pathways, keeper of redox balance and aid in cell membrane stability (3,4). The association between AMD risk and Lutein and Zeaxanthin has been explored in several large scale epidemiological studies. Hock eng khoo *et al.* noted that the high intake of xanthophyll containing foods has been attributed to the elevated levels of plasma

Lutein and zeaxanthin. The elevated level of plasma helped to prevent AMD in the elderly. Johnson *et al.* suggested that consumption of Lutein is recommended to be higher than zeaxanthin amongst all age groups.

According to the eye disease control study, advanced AMD risks are reduced by 43% in those participants who are in the highest quintile of dietary carotenoid intake when compared with the lowest quintile (5). Participants in the top tertile of intake ($\geq 942 \mu\text{g/day}$) had a decreased risk of incident neovascular AMD and those with above intakes (743 μg) had a reduced risk of reticular drusen. In 2006, ARMD study concluded that xanthophyll diets helps to protect against intermediate AMD in female patients less than 75 yrs. of age. (6)

Hock eng *et al* showed that serum concentration of lutein and zeaxanthin are essential for smokers than the non- smokers they have lower macular pigment optical density and shows inflammation of macular pigment among heavy smokers was higher than the non- smokers. Measurement of macular pigment optical density (MPOD) helps to measure the non-invasive retinal lutein and zeaxanthin.

B. OMEGA- 3 FATTY ACIDS:

Main omega 3- fatty are alpha- linolenic acid (ALA- short chain), docosahexaenoic acid (DHA- long chain) and eicosapentaenoic acid (EPA- long chain). Omega 3 fatty acids plays an important role in reducing the strokes or incidence related to cardiovascular disease. In these 3 omega fatty acids, DHA is present in high concentration in the photoreceptor segment of the retina and due to deficiency of DHA it has been involved in AMD onset (7). For advanced AMD, higher intake of DHA and EPA were associated with a lower risk of progression. Those participants who intake highest omega 3- long chain polyunsaturated fatty acids were approx. half as to be expected to take neovascular AMD at baseline. (8,9)

The risk of hemorrhagic stroke is potentially augmented by antithrombotic effect of fish oil (10). With simultaneous administration of agents like warfarin and aspirin, high dose of fish oil does not increase the risk of bleeding (11-13). The FDA issued an advisory statement that pregnant women, breast feeding mothers and children avoid eating seafood high in mercury (14). Fish oil supplements are generally regard as safe because most industrial purification process eliminate these toxins. (15, 16)

2. BERRY EXTRACTS

US department of agriculture published that blueberry shows good antioxidant properties among 100 common food items and claim to protect eyes from AMD. Another berry Wolfberry (Goji berry) also

shows protecting properties which has been long used in traditional Chinese Medicine (TCM). (17, 18) Most of the products of berry extracts should not be recommended because there is no legal requirement for quality controls of these extracts.

3. VITAMINS

It is an essential micronutrient that an organism needs in small quantities for proper functioning but those who consumed increased amounts of fruits and vegetables rich in vitamin A helps to reduce the risk the stage of AMD.

- **VITAMIN C** – It is recognized as ascorbic acid. It is one of the safest and effective antioxidant that protects protein, lipids, carbohydrates and nucleic acids from free radicals and reactive oxygen species (ROS) damage (19). San Giovanni *et al.* revealed that a reduced likelihood of neovascular AMD in subjects reporting high intake of β carotene, vitamin C and vitamin E (20). Christen *et al.* reported that users of vitamin C had a higher risk of macular degeneration than the users of vitamin E. (21)
- **VITAMIN E** – It is powerful and effective antioxidant that helps to repair damage cells and scavenges the free radicals. William G. *et al* revealed that long term alternate day use of 600 IU of natural source vitamin E had no large beneficial or harmful effects on risk of AMD. Due to deficiency it may lead to lipofuscin accumulation (22), retinal damage (23) and loss of photoreceptors (24).

C. MINERALS:

- **ZINC** - In studying eye tissue samples, it is found that deposits, which are hallmarks of ARMD, contain large amounts of zinc. Zinc supplements are mainly given to patients to help boost weak immune systems. Dietary self-administration of

zinc(200mg) daily for up to 24 months had also proven to reduce the visual loss as compared to the placebo group. (25)

According to the systemic review conducted by vishwanathan *et al.* examined the evidence on zinc intake from foods for prevention ARMD and conclude that zinc treatment may be effective in preventing progression to advanced AMD. Zinc supplementation alone may not be sufficient to produce clinically changes in visual perception. (26)

- Selenium also helps in reducing the risk of AMD. Glutathione peroxidase act as mediator to reduce hydrogen peroxides which is present inside the cell. (27)

A low intake of dietary selenium is known to cause a reduction of total polyunsaturated fatty acids (PUFAs) in the retinal pigment epithelium and retinal rod outer segments of laboratory animals. (28)

D. AREDS or AREDS like formulas:

The Age – Related Eye Disease (AREDS) was the first who demonstrated the use of vitamin and mineral supplementation to reduce the progression of advanced AMD by performing randomized clinical trial.

Vitamin A, Vitamin C, vitamin E and Zinc were the main components of this formula. By counteracting oxidative stresses, these constituents exert a protective effect on retinal cells. (29-34)

- AREDS formulation:

Vitamin C	500mg
Vitamin E	400IU
Beta carotene	15mg
Zinc (Zinc oxide+ cupric oxide)	80mg+2mg

They showed 25% risk decline in advance AMD over 5 yrs in patients with intermediate drusen in one or both eyes. (35)

- Potential risks:

Vitamin C	Kidney stones
Vitamin E	Fatigue, muscle weakness, decreased thyroid function and increased hemorrhagic stroke
Beta carotene	Lung cancer, yellow discoloration of skin
Zinc	Decreased drum high density lipoprotein cholesterol (36)

A. GLAUCOMA

2nd leading board disease is glaucoma that causes blindness, which is chronic optic neuropathy characterized by continuous retinal ganglion cells (RGC) axon degeneration and death. Primary (OAG) open angle glaucoma, associated with increased intraocular pressure (IOB) which give glaucoma related neurodegeneration include oxidative stress excitotoxicity, neuroinflammation and impaired ocular blood flow.

According to Indian population, the expected number of cases is about 12 million which is around one fifth of the global burden of glaucoma. Syed zulfequar Ahmad *et al.* had report in their study population that the IOP lied in 11- 15 mm Hg with a mean of 13.42 \pm 4.09 mmHg. The prevalence of OAG (1.3%), primary angle closure glaucoma (1.2%), secondary glaucoma (0.9%), and normotensive (1.2%), therefore overall prevalence was found to be 4.6%.

1. VITAMINS

The damage of RGC vitamins as antioxidants suggested as potential neuroprotective agents. Deficiency of vitamins in glaucoma leads to the symptoms like optic nerve dysfunction, connected between serum vitamins level and glaucoma prevalence in human remains controversial. (37, 38) For example, in 2003, the nurses' health study and health professionals follow up study reported no

strong association between the risk of primary open angle glaucoma and Vitamin C consumption (39). According to a recent meta-analysis by some of the reporters that normal tension glaucoma NTG risk is not associated with serum Vitamin B6, vitamin B12 and Folic acid levels (40).

Wishal D Ramdas *et al.* determined the association of vitamins with glaucoma by performing a systemic review.

VITAMIN	CHEMICAL NAME	MAIN SOURCES	OBSERVATIONS	IMPORTANCE
A	Retinol	Animal products	Retinol active form is immediately available to the body	Important for rhodopsin which act as an antioxidant
		Plant products	Provitamins has to be metabolized into an active form	Important for rhodopsin which act as an antioxidant
B-complex	Thiamin(B1)	Animal / plant products	Some flavonoids may antagonize vitamin B1	Involved in catabolism of amino acids, carboxylase, cell division and growth and DNA synthesis
C	Ascorbic acid	Plant products	Oxidized form of vitamin is reduced by glutathione which maintain vitamin C in reduced form	Important for non- enzymatic antioxidant
D	Cholecalciferol	Sunlight exposure	In the liver vit. D is converted to 25-hydroxyvitamin D which is used as a biomarker	Responsible for intestinal absorption of several minerals such as Ca, Mg and Zn

2. COENZYME Q

The production of adenosine triphosphate (ATP) by oxidative phosphorylation give the cofactor and of that the electron transport chain, a membrane stabilizer gives an essential of coenzyme Q (41,42).

Several studies demonstrated the compound protects retinal cells against oxidative stress in vivo and in vitro

1	Nucci and colleagues	On intraocular administration of coenzyme Q, it was observed by micro dialysis that it affords neuroprotection in the retina of rats subjected to ischemia preventing glutamate increase.(43)
2	Lee and colleagues	Compound inhibits glutamate excitotoxicity and oxidative stredd mediated mitochondrial alteration in glaucomatous DBA/2J mice. It is also preserved mitochondrial DNA content and mitochondrial transcription factor A in the retina.(41)
3	Noh and colleagues	Coenzyme Q protects the optic nerve head (ONH) astrocytes against stress mediated mitochondrial dysfunction or variation in glaucoma.(44)
4	Nakajima and colleagues	Retinal ganglion cells (RGC-5) is a combination of coenzyme Q and trolox and referent of water soluble vitamin E which prevents the cell damage more effectively than the alone.(45)
5	Parisi and colleagues	On administration of coenzyme Q with vitamin E in open angle glaucoma indicates a favorable effect on the retinal function with enhancement of the visual corticol responses.(46)

4. FLAVONOIDS

Flavonoids are used to demonstrate anti-inflammatory and neuroprotective effect that may reduce damage from oxidative stress (47,48) and it is a large family of phytonutrient compound widely distributed and grouped into five main categories (flavonols, flavan-3-ols, flavones, flavanones, and anthocyanidins). It also gives the beneficial effects on multiple disease states including cancer cardiovascular diseases and neurodegenerative disorders (49, 50). In the studies of in Vivo and in vitro also reported the beneficial effects of flavonoids in ocular diseases that shows meta-analysis with no statistically significant effect of flavonoids on lowering intraocular pressure (51). Nakayama and colleagues demonstrated the neuroprotective potential give the three types of flavonoids compound is kaempferol 3-O-rutinoside (nicotiflorin), quercetin 3-O-rutinoside (rutin) and quercitrin using rat under stress conditions (hypoxia, excessive glutamate levels and oxidative stress. Due to these stress conditions all compounds considerably increased the RGC survival rate but nicotiflorin and rutin were more active than quercitrin. (52)

5. CITICOLINE

It is a natural constituent of all cells that serves phosphatidyl choline synthesis (53), and attenuates free fatty acids release and re-established the level of cardiolipin phospholipid components of inner mitochondrial membrane (54) and also increases neurotransmitter levels in a central nervous system (55) and the retina that gives an improvement of retinal and of the visual pathway function in patients with glaucoma (56-58).

For example: - in partial Crush injury of rat optic nerve model practical in was found effective in rescuing RGC and their axons in vivo against delayed degeneration triggered by optic nerve Crush (59). Citicoline increase retinal expression of apoptotic regulating protein Bcl2, indicating one of the mechanism which may be engaged in the neuroprotective effect of a compound (59). Moreover, after intravitreal injections of kainic acid, citicholine counteracts increase expression of NOS isoforms and decreased ERK1/2 kinase activation caused by KA (60), as it is rescued damage of a disease through anti apoptotic effect probably acting as an BDNF mimic that was affected with the

reduction of expression of active forms of caspase 9 and 3. (61)

6. POLYUNSATURATED FATTY ACIDS

The essential fatty acids of polyunsaturated are Omega 3 and Omega 6 both are concentrated in the phospholipids of a cell membranes throughout the human body, but especially in the brain, heart, retina and testes (62). Essentials of Omega 3 and 6 hour of the special interest due to their reported anti-inflammatory, hypolipidemic, and vasodilatory capacities (63,64). Some of the diets with increases Omega 3 and decrease with Omega 6 favor and increase in IOP reducing synthesis of the PG after leading to the decrease in uveoscleral outflow (65). Schenebelen and colleagues confirmed that a sixth month of supplementation with the combination of Omega 3 and Omega 6 phase is more effective than single supplementation since EPA+ DHA (docosahexaenoic acid) + gamma linolenic acid diet combination preventive retinal cell structures and decrease in glial cell activation induced by the elevation of IOP in rats. (66)

B. CATARACT:

Cataract: clouding of the eye's natural lens, results in the loss of vision, due to aging, infection in newborn babies, injury or poor development prior to birth or during childhood, to prevent cataract there is urgent need for inexpensive, non-surgical approaches such as therapeutic action.

- Antioxidants or ROS scavengers
- Aldose Reductase inhibitors
- Antiglycating agents
- Inhibitors of Lens Epithelial Cell apoptosis

1. Antioxidants

To prevent cataract, various antioxidants are used as flavonoids, carotenoids, ascorbic acid, tocopherol, caffeine and pyruvate.

Flavonoids:

Flavonoids are C6-C3-C6 compounds with fifteen carbon atoms. It exerts antioxidant effects due to their ability to scavenge free radicals, donate hydrogen, and act also as singlet oxygen quenchers and metal ion chelators. Examples: myricetin, quercetin, rhamnetin, morin, diosmetin, naringenin, apigenin, catechin, kaempferol and flavones. Obtained from fruits such as apple, grapes, bananas, cherries and from green leafy vegetables.

Flavonoids are also referred as vitamin P, they are found as a highly potent inhibitors of aldose reductase.

The best described biological activity of this group covered by number of excellent reviews:

Hamasaki <i>et al.</i> , 1994	Flavonoids inhibits xanthine oxidase, the enzyme responsible for superoxide anion production
Nagao <i>et al.</i> , 1999	3- methyl quercetin was found to inhibit xanthine oxidase, even more efficiently than the aglycone form of quercetin
Bors and Michael <i>et al.</i> 2002	Presence of 3 hydroxyl group increases the radical scavenging activity
Butkovic <i>et al.</i> , 2004	Flavonoids were found to scavenge efficiently the model free radicals of 2,2 – diphenyl- 1-picrylhydrazyl and α,γ - bisdiphenylene- β phenylallyl
Amic <i>et al.</i> 2007	Quercitin is the most scavenger of reactive oxygen species

Vitamins:

1. Vitamin A	It is a component of the protein rhodopsin which helps to see in light conditions.
2. Vitamin E	Alpha tocopherol is a component of vitamin E which has powerful antioxidant properties. Corn oil and wheat germ oil are common source of vitamin E. It has also antioxidant property that helps protect against oxidative damage. It
3. Vitamin C	preserves glutathione level and protect the Na / k pump. (67,68)They are mainly found in Amla and other citrus fruits.
4. Vitamin B	It helps to reduce the rate of nuclear cataract which occur deep in its centre or nucleus.

Robertson JM *et al.* revealed that cataract patients tended to have lower serum levels of vitamin C and E than the control subjects. Biochemical evidence suggests that oxidative stress caused by accumulation of free radicals is involved in the pathogenesis of senile cataracts, therefore it might be expected that vitamins C and E prevent or retard the process.

Carotenoids: From family of 700 compounds of carotenoid, 20 have been detected in human plasma and tissues from these two Lutein and zeaxanthin are two dietary carotenoids which are present in human eye lens. It has been reported that these compounds can filter harmful short wave blue light which reduce H₂O₂ mediated damage of lens protein, lipid and DNA (69), and function as antioxidants by stabilize membrane integrity. Astaxanthin is one of the carotenoid which has 100-fold higher antioxidant activity than Alpha tocopherol, due to this it is called as 'super vitamin E'

An in vivo study conducted in quails confirmed that lens carotenoid can be increased by dietary intake of zeaxanthin and in streptozotocin- induced diabetic rats showed that intake of lutein supplementation was effective in preventing and progression of cataract. (70, 71)

2. Aldose reductase inhibitors

Polyol sorbitol accumulated in the lens that cause diabetic cataract (72, 73, 74). The enzyme aldose reductase presents in the lens which converts glucose into sorbitol and the reason for accumulation of sorbitol in eye lens. To prevent the diabetic cataract Aldose Reductase inhibitors can be used as therapeutic agents. (75, 76)

Some flavonoids inhibit aldose reductase activity at different extent. Mainly quercetrin and their derivatives show 100% inhibition activity.

A recent study was demonstrated by Varma *et al.* that the administration of pyruvate prevented cataract development by inhibiting the activity of aldose reductase in diabetic rats.

3. Antiglycating agents

These agents' help in prevention of cataract are: **Polyphenols, Polysaccharides.**

Polyphenols:

Polyphenols are dietary antioxidants, which are commonly found in fruits, vegetables, cereals, seeds, nuts, chocolate and beverages such as coffee, tea, and wine. They show strong Antiglycating activity. Based on their chemical structure, these are classified as phenolic acids and flavonoids.

Terpenes, carotenoids and polyunsaturated fatty acids:

A terpene 8 (17), 12-Labdadiene-15, 16-dial (labdadiene) and 5, 6-dehydrokawain (DK) abstract from the rhizome of *Alpinia zerumbet*, which have potential to inhibit glycation-induced protein oxidation.

Number of antioxidants such as carotenoids, polyunsaturated fatty acids and polysaccharides can be produced in microalgae. (77)

Polysaccharides:

The pericarp fruit (*Dimocarpus longan*) contains polysaccharide that acts as free radical scavenger which competes with glucose for binding to free amino group in proteins, which also reduces the concentration of glycation targets in proteins (78). Polysaccharides from pumpkin (*Cucurbita*

moschata) have also shown antiglycating activity. (79)

4. Inhibitors of Lens Epithelial Cell Apoptosis

Oxidative stress is the major cause of Human cell epithelial (HPE) cell apoptosis which leads to cataract formation (80)

Xing chao *et al* explored the effect of parthenolide on hydrogen peroxide induced apoptosis in human lens epithelial (HLE) cells. Parthenolide is component of *tanacetum parthenium*.

To induce apoptosis, different concentrations (50, 100, 200 $\mu\text{mol/L}$) of H_2O_2 were treated with HLE cells. Only the 200 $\mu\text{mol/L}$ H_2O_2 caused a morphological change such as cytoplasmic condensation and increased in intercellular gaps.

PARTHENOLIDE

A. Modulate apoptosis by regulating signaling pathways such as

- Nuclear factor- kb (Involved in H_2O_2 Induced damage to HLE cells)
- Phosphoinositide 3- kinase (PI3K)
- Mitogen activated protein kinases (MAPKs)
- Extracellular signal regulated kinases (ERK1)

Both MAPKs and ERK1 increased proliferation in tumor cells and its inhibitors have become Anticancer agents. (81, 82, 83)

B. Impacts the treatment of inflammation by inhibiting nuclear factor- kb activation (84).

Sumeer singh *et al.* had report the cataract population in south India and revealed the prevalence of cataract about 44.6%, 43.6% in the rural, urban population respectively. R Aarthi *et al.* had report that the prevalence of cataract among male was 66.9% (95% CI: 58.2- 74.8%) and 60.4% in female (95% CI: 53.7- 66.9%).

CONCLUSION:

Nutraceutical are present in most of the food ingredients with varying concentration. By manipulating the foods, the concentration of active ingredients can be increased. By implementing one or more mechanism singly or simultaneously of nutraceutical, they play their important role in prevention of ophthalmic disease. Nutraceutical mostly followed the mechanism of antioxidants and vitamins in age related eye disease. Due to high doses of natural dietary supplements, toxicology aspects have to be considered. Due to lack of plenty evidence in elderly people for primary prevention ARMD, antioxidant supplements should not be considered regularly. Antioxidant supplements in ARMD, lutein and zeaxanthin are commonly used in diagnosed ARMD to slow the progression of ARMD. In Glaucoma management, nutraceutical may

provide some therapeutic potential but due to lack of clinical trials limit their current therapeutic use.

REFERENCES:

1. Kanski J, Bowling B (2016) Kanski clinical ophthalmology. 8th edition, China, Elsevier 928.
2. Klaver CC, Assink JJ, Van Leeuwen R, Wolfs RC, *et al.* Incidence and progression rates of age-related maculopathy, the Rother Dam Study. Invest Ophthalmol Vis Sci 2001; 42: 2237-41.
3. Klein R, Klein BEK, Linton KLP. Prevalence of age related maculopathy: The Beaver Dam Study. Ophthalmology 1992;99:933-43.
4. Vingerling JR, Diclemans I, Hofman A, *et al.* The prevalence of age-related maculopathy in the Rotherdam Study. Ophthalmology 1995; 102: 205-10.
5. Mitchel P, Smith W, Altebo K, *et al.* Prevalence of age-related maculopathy in Australia: The Blue Mountain Study. Ophthalmology 1995; 102: 1450-60.
6. Sujak A, Gabrielska J, Grudzinski W, Borc R, *et al.* Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects. Arch Biochem Biophys. 1999;371: 301-307.
7. Ma. L., Lin X. M. Effects of lutein and zeaxanthin on aspects of eye health J. Science. Food agriculture. 2010; 90:2 -12.
8. Rosenthal JM, kim J, Monastario F, *et al.* Dose ranging study of lutein supplementation in persons aged 60 yrs or older. Invest ophthalmol vis science 2006; 47:5227 – 5233.
9. Whitehead AJ, Mares JA, Danis RP. Macular pigment: a review of current knowledge. Arch ophthalmol. 2006; 124:1038-1045
10. Seddom JM, Ajani UA, Sperduto RD, *et al.* Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA. 1994; 272:1413–20.
11. Age-Related Eye Disease Study Research Group. The relationship of dietary carotenoids and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS report no. 22. Arch Ophthalmol. 2007; 125:1225–1232.
12. Bazan NG. The metabolism of omega-3 polyunsaturated fatty acids in the eye: the possible role of docosahexaenoic acid and docosanoids in retinal physiology and ocular pathology. Prog Clin Biol Res. 1989; 312:95–112.
13. SanGiovanni JP, Chew EY, Clemons TE, *et al.* Age-Related Eye Disease Study Research Group The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS report No. 20. Arch Ophthalmol. 2007; 125:671–679.
14. SanGiovanni JP, Chew EY, Agrón E, *et al.* Age-Related Eye Disease Study Research Group The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report No. 23. Arch Ophthalmol. 2008; 126:1274–1279. The results of this study from the AREDS group suggest that dietary omega-3 fatty acid intake is associated with a

- decreased risk of progression from bilateral drusen to central geographic atrophy.
15. Carroll DN, Roth MT (2002) Evidence for the cardioprotective effects of omega-3 fatty acids. *Ann Pharmacother* 36:1950–1956.
 16. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M (1996) Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. *Am J Cardiol* 77:31–36
 17. Leaf A, Jorgensen MB, Jacobs AK *et al* (1994) Do fish oils prevent restenosis after coronary angioplasty? *Circulation* 90:2248–2257
 18. Bender NK, Kraynak MA, Chiquette E, Linn WD, Clark GM, Bussey HI (1998) Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. *J Thromb Thrombolysis* 5:257–261
 19. US Department of Health and Human Services, US Environmental Protection Agency. What you need to know about mercury in fish and shellfish. CFSAN Website.
 20. Foran SE, Flood JG, Lewandrowski KB (2003) Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? *Arch Pathol Lab Med* 127:1603–1605
 21. Good news! These supplements have omega-3's without contaminants found in fish! But some are better than others. ConsumerLab.com Website.
 22. Dietary Guidance, National Agricultural Library, United States Department of Agriculture website. http://riley.nal.usda.gov/nal_display/index.php
 23. Wang X, Hu S (2001) A review of research actuality on age-related macular degeneration. *Yan Ke Xue Bao* 17(4):245–251
 24. Zampatti S., Ricci F., Cusumano A., Marsella L.T., Novelli G., Giardina E. Review of nutrient actions on age-related macular degeneration. *Nutr. Res.* 2014; 34:95–105. doi: 10.1016/j.nutres.2013.10.011.
 25. SanGiovanni J.P., Chew E.Y., Clemons T.E., Ferris F.L., II, Gensler G., Lindblad A.S., Milton R.C., Seddon J.M., Sperduto R.D. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study. *Arch Ophthalmol.* 2007; 125:1225–1232.
 26. Christen W.G., Ajani U.A., Glynn R.J., Manson J.E., Schaumberg D.A., Chew E.C., Buring J.E., Hennekens C.H. Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy. *Am. J. Epidemiol.* 1999; 149:476–484.
 27. Robison W.G., Kuwabara T., Bieri J.G. The roles of vitamin E and unsaturated fatty acids in the visual process. *Retina.* 1982; 2:263–281.
 28. Tanito M., Yoshida Y., Kaidzu S., Chen Z.-H., Cynshi O., Jishage K.-I., Niki E., Ohira A. Acceleration of age-related changes in the retina in a-tocopherol transfer protein null mice fed a vitamin E-deficient diet. *Investig. Ophthalmol. Vis. Sci.* 2007; 48:396–404.
 29. Katz M.L., Eldred G.E. Failure of vitamin E to protect the retina against damage resulting from bright cyclic light exposure. *Investig. Ophthalmol. Vis. Sci.* 1989; 30:29–36.
 30. Newsome D.A., Swartz M., Leone N.C., Elston R.C., Miller E. Oral zinc in macular degeneration. *Arch. Ophthalmol.* 1988; 106:192–198.
 31. Vishwanathan R., Chung M., Johnson E.J. A systematic review on zinc for the prevention and treatment of age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* 2013; 54:3985–3998.
 32. Eye Disease Case-Control Study Group Antioxidant status and neovascular age-related macular degeneration. *Arch. Ophthalmol.* 1993; 111:104–109.
 33. Farnsworth C.C., Stone W.L., Dratz E.A. Effects of vitamin E and selenium deficiency on the fatty acid composition of rat retinal tissues. *Biochim. Biophys. Acta.* 1979; 552:281–293.
 34. Seddon JM, Ajani UA, Sperduto RD, Eye Disease Case-Control Study Group *et al* (1994) Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. *JAMA* 272:1413–1420
 35. Snellen EL, Verbeek AL, Van Den Hoogen GW, Cruysberg JR, Hoyng CB (2002) Neovascular age-related macular degeneration and its relationship to antioxidant intake. *Acta Ophthalmol Scand* 80:368–371
 36. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO (1988) Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. *Am J Epidemiol* 128:700–710
 37. VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, Palta M (1998) Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. *Am J Epidemiol* 148:204–214
 38. Newsome DA, Swartz M, Leone MC, Elston RC, Miller E (1988) Oral zinc in macular degeneration. *Arch Ophthalmol* 106:192–198
 39. Moriarty-Craige SE, Ha K-N *et al* (2007) Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. *Am J Ophthalmol* 143:206–211
 40. The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. *Arch Ophthalmol.* 2001; 119:1417–36.
 41. Klein R, Peto T, Bird A *et al* (2004) The epidemiology of age-related macular degeneration. *Am J Ophthalmol* 137:486–495
 42. Veach J. Functional dichotomy: glutathione and vitamin E in homeostasis relevant to primary open-angle glaucoma. *Br. J. Nutr.* 2004;91(6):809–829.
 43. West A.L., Oren G.A., Moroi S.E. Evidence for the use of nutritional supplements and herbal medicines in common eye diseases. *Am. J. Ophthalmol* 2006; 141(1):157–166.
 44. Kang J.H., Pasquale L.R., Willett W., Rosner B., Egan K.M., Faberowski N., Hankinson S.E. Antioxidant intake and primary open-angle glaucoma: a prospective study. *Am. J. Epidemiol.* 2003;158(4):337–346.

45. Li J., Xu F., Zeng R., Gong H., Lan Y. Plasma homocysteine, serum folic acid, serum vitamin B12, serum vitamin B6, MTHFR, and risk of normal-tension glaucoma. *J. Glaucoma*. 2016;25(2): e94–e98.
46. Lee D., Shim M.S., Kim K.Y., Noh Y.H., Kim H., Kim S.Y., Weinreb R.N., Ju W.K. Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma. *Invest. Ophthalmol. Vis. Sci*. 2014;55(2): 993–1005.
47. Nakajima Y., Inokuchi Y., Nishi M., Shimazawa M., Otsubo K., Hara H. Coenzyme Q10 protects retinal cells against oxidative stress *in vitro* and *in vivo*. *Brain Res*. 2008; 1226:226–233.
48. Nucci C., Tartaglione R., Cerulli A., Mancino R., Spanò A., Cavaliere F., Rombolà L., Bagetta G., Corasaniti M.T., Morrone L.A. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. *Int. Rev. Neurobiol*. 2007; 82:397–406.
49. Noh Y.H., Kim K.Y., Shim M.S., Choi S.H., Choi S., Ellisman M.H., Weinreb R.N., Perkins G.A., Ju W.K. Inhibition of oxidative stress by coenzyme Q10 increases mitochondrial mass and improves bioenergetic function in optic nerve head astrocytes.
50. Nakajima Y., Inokuchi Y., Nishi M., Shimazawa M., Otsubo K., Hara H. Coenzyme Q10 protects retinal cells against oxidative stress *in vitro* and *in vivo*. *Brain Res*. 2008;1226:226–233.
51. Parisi V., Centofanti M., Gandolfi S., Marangoni D., Rossetti L., Tanga L., Tardini M., Traina S., Ungaro N., Vetrugno M., Falsini B. Effects of coenzyme Q10 in conjunction with vitamin E on retinal-evoked and cortical-evoked responses in patients with open-angle glaucoma. *J. Glaucoma*. 2014;23(6):391–404.
52. Ishige K., Schubert D., Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. *Free Radic. Biol. Med*. 2001;30(4):433–446.
53. Milbury P.E. Flavonoid intake and eye health. *J. Nutr. Gerontol. Geriatr*. 2012;31(3):254–268.
54. Middleton E., Jr Effect of plant flavonoids on immune and inflammatory cell function. *Adv. Exp. Med. Biol*. 1998; 439:175–182.
55. Kozłowska A., Szostak-Wegierek D. Flavonoids--food sources and health benefits. *Rocz. Panstw. Zakl. Hig*. 2014;65(2):79–85.
56. Patel S., Mathan J.J., Vaghefi E., Braakhuys A.J. The effect of flavonoids on visual function in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. *Graefes Arch. Clin. Exp. Ophthalmol*. 2015; 253(11):1841–1850.
57. Nakayama M., Aihara M., Chen Y.N., Araie M., Tomita-Yokotani K., Iwashina T. Neuroprotective effects of flavonoids on hypoxia-, glutamate-, and oxidative stress-induced retinal ganglion cell death. *Mol. Vis*. 2011; 17:1784–1793.
58. Grieb P., Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. *J. Neurosci. Res*. 2002;67(2):143–148.
59. Roberti G., Tanga L., Michelessi M., Quaranta L., Parisi V., Manni G., Oddone F. Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives. *Int. J. Mol. Sci*. 2015;16(12):28401–28417.
60. Martinet M., Fonlupt P., Pacheco H. Effects of cytidine-5' diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. *Arch. Int. Pharmacodyn. Ther*. 1979; 239(1):52–61.
61. Pecori Giralaldi J., Virno M., Covelli G., Grechi G., De Gregorio F. Therapeutic value of citicoline in the treatment of glaucoma computerized and automated perimetric investigation. *Int. Ophthalmol*. 1989;13(1-2):109–112.
62. Virno M., Pecori-Giralaldi J., Liguori A., De Gregorio F. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). *Acta Ophthalmol. Scand. Suppl*. 2000;232(232):56–57.
63. Parisi V., Manni G., Colacino G., Bucci M.G. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. *Ophthalmology*. 1999;106(6):1126–1134.
64. Schuettauf F., Rejdak R., Thaler S., Bolz S., Lehaci C., Mankowska A., Zarnowski T., Junemann A., Zagorski Z., Zrenner E., Grieb P. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. *Exp. Eye Res*. 2006;83(5):1128–1134.
65. Park C.H., Kim Y.S., Cheon E.W., Noh H.S., Cho C.H., Chung I.Y., Yoo J.M., Kang S.S., Choi W.S., Cho G.J. Action of citicoline on rat retinal expression of extracellular-signal-regulated kinase (ERK1/2). *Brain Res*. 2006;1081(1):203–210.
66. Oshitari T., Yoshida-Hata N., Yamamoto S. Effect of neurotrophic factors on neuronal apoptosis and neurite regeneration in cultured rat retinas exposed to high glucose. *Brain Res*. 2010; 1346:43–51.
67. Huang W.B., Fan Q., Zhang X.L. Cod liver oil: a potential protective supplement for human glaucoma. *Int. J. Ophthalmol*. 2011;4(6):648–651.
68. Den Ruijter H.M., Berecki G., Ophhof T., Verkerk A.O., Zock P.L., Coronel R. Pro- and antiarrhythmic properties of a diet rich in fish oil. *Cardiovasc. Res*. 2007;73(2):316–325.
69. Wall R., Ross R.P., Fitzgerald G.F., Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. *Nutr. Rev*. 2010;68(5):280–289.
70. Desmettre T., Rouland J.F. Hypothesis on the role of nutritional factors in ocular hypertension and glaucoma. *J. Fr. Ophthalmol*. 2005;28(3):312–316.
71. Schnebelen C., Pasquis B., Salinas-Navarro M., Joffre C., Creuzot-Garcher C.P., Vidal-Sanz M., Bron A.M., Bretillon L., Acar N. A dietary combination of omega-3 and omega-6 polyunsaturated fatty acids is more efficient than single supplementations in the prevention of retinal damage induced by elevation of intraocular pressure in rats. *Graefes Arch. Clin. Exp. Ophthalmol*. 2009;247(9):1191–1203.
72. Ohta Y, Niwa T, Yamasaki T. Effect of prolonged marginal ascorbic acid deficiency on lenticular levels of antioxidants and lipid peroxide in guinea pig. *Int J VITAMIN Nutr Res*. 2001;71: 103-9

73. Mody VC, Kakar M, Elfving A, Soderberg PG, Lofgren S. Ascorbate in the rat lens: dependence on dietary intake. *Ophthalmic Res.* 2005; 37:142-9.
74. Gao S., Qin T., Liu Z. Lutein and zeaxanthin supplementation reduces H₂O₂ induced oxidative damage in human lens epithelial cells. *Mol. Vision.* 2011; 17:3180-3190.
75. Dorey CK, Granata L, Nicholas CR, Cheng KM, Craft NE (2005) Dietary modulation of lens and zeaxanthin in quail. *Res* 81: 464- 477
76. Arnal E, Miranda M, Almansa I, Muriach M, Barcia JM, Romero FJ, Diaz- Llopis M, Bosch – morell F (2009) Lutein prevents cataract development and progression in diabetic rats, 247:115-120
77. Chihiro Y.N. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. *Pharmacol Rev.* 1998; 50:21-33.
78. Alexiou P., Pegklidou K., Chatzopoulou M. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. *Curr Med Chem.* 2009; 16:734-752.
79. Del Corso A., Cappiello M., Mura U. From a dull enzyme to something else: facts and perspectives regarding aldose reductase. *Curr Med Chem.* 2008; 15:1452-1461.
80. Costantino L., Rastelli G., Gamberini M.C. Pharmacological approaches to the treatment of diabetic complications. *Expert Opin Ther Patents* .2000; 10:1245-1262.
81. Miyamoto S. Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications. *Expert Opin Ther Patents* .2002; 12:621-631.
82. Chen F. High cell density culture of microalgae in heterotrophic growth. *Trends Biotechnol.* 1996; 14: 421-426.
83. Yang B., Zhao M.M., Shi J. Variations in water-soluble saccharides and phenols in longan fruit pericarp after drying. *J Food Process Eng.* 2008; 31:66-77.
84. Wang X., Zhang L.S., Dong L.L. Inhibitory effect of polysaccharides from pumpkin on advanced glycation end-products formation and aldose reductase activity. *Food Chem.* 2010; 120:261-267.
85. Li L, Duker JS, Yoshida Y, Niki E, Rasmussen H, Russell RM, Yeum KJ. Oxidative stress and antioxidant status in order adults with early cataract. *Eye lond* 2009;23 (6):1464- 1468
86. Pozarowski P, Halicka DH, Darzynkiewicz Z. Cell cycle effects and caspase-dependent and independent death of HL-60 and Jurkat cells treated with the inhibitor of NF-kappaB parthenolide. *Cell Cycle.* 2003;2(4):377-383.
87. Lin M, Bi H, Yan Y, Huang W, Zhang G, Zhang G, Tang S, Liu Y, Zhang L, Ma J, Zhang J. Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/ MAPK/ Erk path way. *Oncotarget.* 2017;8(14):23436-23447.
88. Nakabayashi H, Shimizu K. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. *BMC Cancer.* 2012; 12:453.
89. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. *Chem Biol.* 2001;8(8) :759-766.